Product Description: Narlumosbart (JMT103) is an IgG4κ antibody targeting receptor activator of nuclear factor-κB ligand (RANKL)[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. MAbs. 2023 Jan-Dec;15(1):2153410.
CAS Number: 2646587-68-8
Molecular Weight: N/A
Research Area: cancer
Solubility: 10 mM in DMSO
Target: RANKL/RANK